Affiliation: University of North Carolina
Toffoli G, Sharma M, Marangon E, Posocco B, Gray E, Mai Q, et al
. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017;23:918-924 pubmed publisher
..The antitumor efficacy of these genotype-guided doses should be tested in future studies of patients with mCRC treated with FOLFIRI plus bevacizumab. Clin Cancer Res; 23(4); 918-24. Â©2016 AACR. ..
Innocenti F, Ramirez J, Obel J, Xiong J, Mirkov S, Chiu Y, et al
. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013;23:374-81 pubmed publisher
..A-priori selection of candidate genes guided by in-vitro metabolic screening enhanced our ability to identify genetic determinants of interpatient pharmacokinetic variability. ..
Crona D, Skol A, Leppänen V, Glubb D, Etheridge A, Hilliard E, et al
. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019;79:231-241 pubmed publisher
..SIGNIFICANCE: Clinical and mechanistic data identify germline genetic variants in VEGFA and FLT4 as markers of survival in patients with metastatic renal cell carcinoma. ..